Arctos Medical

Kostas Kaloulis, the CEO of Arctos and a venture partner at +ND Capital, expressed excitement over Novartis' recognition of the unique optogenetics technology developed by Arctos. He emphasized the potential value and differentiated profile of the technology. As a global leader in ophthalmology, Novartis is well positioned to rapidly advance the program into the clinic, which is anticipated to deliver transformative therapies for underserved patients.